SPOTLIGHT: Merck sees gains with experimental HIV therapy

Merck announced that its experimental MK-0518 significantly reduced HIV virus levels in a mid-stage clinical trial. The drug blocks an enzyme that is needed to allow the virus to penetrate a cell and was used in 35 patients over 10 days. Report

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.